Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
French biotech company NicOx has signed an agreement with the fine chemicals maker Archimica for commercial production of the active pharmaceutical ingredient (API) naproxcinod. Naproxcinod is NicOx' lead product and the first compound in the COX-inhibiting nitric oxide-donating (CINOD) class of anti-inflammatory agents. NicOx expects to file a New Drug Application with FDA by mid-2009. Under the agreement, Archimica will supply the API from its site in Springfield, Mo.; commercial deliveries are expected by fourth-quarter 2009.
This article has been sent to the following recipient: